|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.390 USD | -3.47% |
|
-19.65% | -26.06% |
| 06-15 | Waldencast plc Announces Fda Approval of Obagi Saypha Chiq Injectable Hyaluronic Acid Gel | CI |
| 06-15 | Waldencast Says US FDA Approves Obagi Saypha ChIQ Injectable Hyaluronic Acid Gel | MT |
Turnover - Evolution of Analysts' Estimates
Earnings Per Share (EPS) - Evolution of Analysts' Estimates
EBIT - Evolution of Analysts' Estimates
Cash or Net Debt - Evolution of Analysts' Estimates
| 1m. Revenue rev. | 1y. Revenue rev. | 1y. EPS revision | ||
|---|---|---|---|---|
 | ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| Average | ||||
| Weighted average by Cap. |
Turnover
Earnings Per Share (EPS)
EBIT
Cash or Net Debt
- Stock Market
- Stocks
- WALD Stock
- Consensus Waldencast plc
- Estimates Revisions
Select your edition
All financial news and data tailored to specific country editions
